54 related articles for article (PubMed ID: 38505675)
1. Immunotherapeutic approaches for the treatment of breast cancer.
Knutson KL; Schiffman K; Rinn K; Disis ML
J Mammary Gland Biol Neoplasia; 1999 Oct; 4(4):353-65. PubMed ID: 10705919
[TBL] [Abstract][Full Text] [Related]
2. Introduction of a new recombinant vaccine based on GRP78 for breast cancer immunotherapy and evaluation in a mouse model.
Zare H; Bakherad H; Nasr Esfahani A; Norouzi M; Aghamollaei H; Mousavi Gargari SL; Mahmoodi F; Aliomrani M; Ebrahimizadeh W
Bioimpacts; 2024; 14(2):27829. PubMed ID: 38505675
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
4. Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer.
Niavarani SR; St-Cyr G; Daniel L; Lawson C; Giguère H; Alkayyal AA; Tai LH
Front Immunol; 2023; 14():1098344. PubMed ID: 36860852
[TBL] [Abstract][Full Text] [Related]
5. Staphylococcal enterotoxin B as DNA vaccine against breast cancer in a murine model.
Halabian R; Jahangiri A; Sedighian H; Behzadi E; Fooladi AAI
Int Microbiol; 2023 Nov; 26(4):939-949. PubMed ID: 36991248
[TBL] [Abstract][Full Text] [Related]
6. Preparation of chitosan nanoparticle containing recombinant CD44v antigen and evaluation of its immunization capacity against breast cancer in BALB/c mice.
Gheybi E; Asoodeh A; Amani J
BMC Cancer; 2023 Feb; 23(1):134. PubMed ID: 36759786
[TBL] [Abstract][Full Text] [Related]
7. Cancer vaccines as promising immuno-therapeutics: platforms and current progress.
Liu J; Fu M; Wang M; Wan D; Wei Y; Wei X
J Hematol Oncol; 2022 Mar; 15(1):28. PubMed ID: 35303904
[TBL] [Abstract][Full Text] [Related]
8. Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies.
Hernandez I; Cohen M
Cancer Lett; 2022 Jan; 524():1-14. PubMed ID: 34637844
[TBL] [Abstract][Full Text] [Related]
9. Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer.
Farshbaf M; Khosroushahi AY; Mojarad-Jabali S; Zarebkohan A; Valizadeh H; Walker PR
J Control Release; 2020 Dec; 328():932-941. PubMed ID: 33129921
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of a novel nanobody for detection of GRP78 expressing cancer cells.
Aghamollaei H; Ghanei M; Rasaee MJ; Latifi AM; Bakherad H; Fasihi-Ramandi M; Taheri RA; Gargari SLM
Biotechnol Appl Biochem; 2021 Apr; 68(2):239-246. PubMed ID: 32270531
[TBL] [Abstract][Full Text] [Related]
11.
Khatibi AS; Roodbari NH; Majidzade-A K; Yaghmaei P; Farahmand L
Immunotherapy; 2019 Dec; 11(18):1555-1567. PubMed ID: 31865872
[No Abstract] [Full Text] [Related]
12.
Parvizpour S; Razmara J; Pourseif MM; Omidi Y
Bioimpacts; 2019; 9(1):45-56. PubMed ID: 30788259
[No Abstract] [Full Text] [Related]
13. Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice.
Gheybi E; Salmanian AH; Fooladi AAI; Salimian J; Hosseini HM; Halabian R; Amani J
Iran J Basic Med Sci; 2018 Jan; 21(1):26-32. PubMed ID: 29372033
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
